Top Markets
#1 Helium Helium +111.70%
#2 MowCat MowCat +87.96%
#3 Seeker Seeker +59.64%
#4 UnifAI Network UnifAI Network +35.38%
#5 TENDIES TENDIES +30.15%
#6 pipedog pipedog +23.48%
#7 Zylo Ecosystem Zylo Ecosystem +22.00%
#8 Bounce Bounce +20.25%
#9 Tensor Tensor +19.72%
#10 Pons Pons +19.15%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Sangamo Therapeutics, Inc. Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

GBY
Rank in Stocks #11086
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines designed to significantly improve patients' lives. The company employs cutting-edge platform technologies, including gene therapy, cell therapy, genome editing, and genome regulation. Central to their technological approach is the zinc finger protein (ZFP) platform, which provides both ZFP nucleases for precise DNA sequence modification (allowing for gene addition or knockout) and ZFP transcription factors for upregulating or downregulating gene expression. Their development pipeline includes SB-525, currently in a Phase III AFFINE clinical trial for hemophilia A; ST-920, a gene therapy in Phase I/II STAAR trials for Fabry disease; and SAR445136, a cell therapy undergoing Phase I/II PRECIZN-1 trials for sickle cell disease. Additionally, Sangamo is advancing TX200, a chimeric antigen receptor for HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502 for synucleinopathies, which include Parkinson's disease and other neuromuscular disorders. The company maintains extensive collaborative and strategic partnerships with prominent organizations such as Biogen MA, Inc., Pfizer Inc., Sanofi S.A., Novartis Institutes for BioMedical Research, Inc., and F. Hoffmann-La Roche Ltd. Originally incorporated in 1995 as Sangamo BioSciences, Inc., the company adopted its current name in January 2017 and is headquartered in Brisbane, California.
Share Price
$5.21
Last synced: 2022-08-11
Market Cap
$745.49M
Change (1 day)
0.15%
Change (1 year)
0.00%
Country
US
Trade Sangamo Therapeutics, Inc. (GBY)

Category

Healthcare
Revenue for Sangamo Therapeutics, Inc. (GBY)
Revenue in Aug 2026 TTM: 0
According to Sangamo Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sangamo Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH